Clinical Trial Update: Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating MAL 16.8% cream for actinic keratosis of the face compared to vehicle; study completed with posted results in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (Methyl aminolevulinate hydrochloride)

Snippet

Sponsor: Galderma R&D | Conditions: Actinic Keratoses | Phase 3 | Status: COMPLETED | Results posted: 2022-04-01